| 000 | 01789 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514055249.0 | ||
| 264 | 0 | _c20030604 | |
| 008 | 200306s 0 0 eng d | ||
| 022 | _a0885-3185 | ||
| 024 | 7 |
_a10.1002/mds.10312 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSegovia, Gregorio | |
| 245 | 0 | 0 |
_aEffects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. _h[electronic resource] |
| 260 |
_bMovement disorders : official journal of the Movement Disorder Society _cFeb 2003 |
||
| 300 |
_a138-49 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenergic Uptake Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBehavior, Animal _xdrug effects |
| 650 | 0 | 4 | _aCannabinoid Receptor Modulators |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aFatty Acids, Unsaturated _xpharmacology |
| 650 | 0 | 4 |
_aHyperkinesis _xchemically induced |
| 650 | 0 | 4 |
_aLevodopa _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aReceptors, Cannabinoid |
| 650 | 0 | 4 |
_aReceptors, Drug _xdrug effects |
| 650 | 0 | 4 |
_aReserpine _xtherapeutic use |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aMora, Francisco | |
| 700 | 1 | _aCrossman, Alan R | |
| 700 | 1 | _aBrotchie, Jonathan M | |
| 773 | 0 |
_tMovement disorders : official journal of the Movement Disorder Society _gvol. 18 _gno. 2 _gp. 138-49 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/mds.10312 _zAvailable from publisher's website |
| 999 |
_c12341010 _d12341010 |
||